PL-3994 / Palatin Technologies - LARVOL DELTA

Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects (clinicaltrials.gov) - P2; N=55; Recruiting; Sponsor: Palatin Technologies; Trial completion date: Nov 2021 ➔ Mar 2023; Trial primary completion date: Oct 2021 ➔ Mar 2022

Clinical • Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects (clinicaltrials.gov) - P2; N=55; Recruiting; Sponsor: Palatin Technologies; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure

Noble Financial Equity Conference (Palatin) - PL-3994 / Palatin; Anticipated corporate collaboration target in H1 '12 for acute asthma

Anticipated corporate collaboration • Cardiovascular

Palatin Technologies' (PTN) CEO Carl Spana on Q1 2015 results - Earnings call transcript (SeekingAlpha) - "Regarding...intellectual property portfolio, [Palatin Technologies] obtained several patents, which include...use of Palatin's PL-3994 natriuretic peptide receptor product candidate for the treatment of acute asthma..."

Patent • Asthma